<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02203630</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 140141</org_study_id>
    <secondary_id>UL1RR024975-01</secondary_id>
    <secondary_id>UL1TR000445-06</secondary_id>
    <nct_id>NCT02203630</nct_id>
  </id_info>
  <brief_title>Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients</brief_title>
  <official_title>A Randomized Controlled Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a condition that is marked by severe infection causing hypotension requiring
      vasopressors to maintain adequate perfusion to vital organs. The Surviving Sepsis campaign,
      an international organization formed for the purpose of guiding the management of sepsis and
      septic shock, currently recommends norepinephrine as the first-choice vasopressor for septic
      shock. Phenylephrine, a vasopressor FDA-approved for use in septic shock, is recommended as
      an alternative vasopressor when septic shock is complicated by tachyarrhythmia to mitigate
      cardiac complications. This recommendation is based solely on experience with no scientific
      evidence to support this recommendation.

      The investigators will conduct an open-label randomized controlled trial (RCT) directly
      comparing phenylephrine and norepinephrine, two FDA-approved vasopressors that are both used
      in clinical practice for the management of septic shock. The investigators will perform this
      study with a population of patients that have septic shock to complete the following aims:

      Aim 1: Determine the incidence of tachyarrhythmias.

      Aim 2: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a
      lower heart rate.

      Aim 3: Determine which vasopressor, phenylephrine or norepinephrine, is associated with a
      higher incidence of new tachyarrhythmias.

      Aim 4: Determine which vasopressor, phenylephrine or norepinephrine, is associated with less
      time in tachyarrhythmia.

      Aim 5: Determine which vasopressor, phenylephrine or norepinephrine, is associated with fewer
      complications, including cardiac complications.

      The investigators hypothesize that in this setting, phenylephrine will improve the management
      of septic shock when used as a &quot;first choice&quot; vasopressor by:

        1. Decreasing the mean heart rate

        2. Decreasing the incidence of new tachyarrhythmias

        3. Decreasing the amount of time spent in tachyarrhythmia for patients who develop new
           onset and recurrent tachyarrhythmias

        4. Decreasing the number of cardiac complications
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment; Lack of support and equipoise
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Heart Rate</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Arrhythmia Events</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Time in Arrhythmia</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With ST-segment Abnormalities on ECG</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>ST Elevation of 1 mm in 2 or more consecutive leads or Horizontal or downsloping ST depression of 1 mm in 2 or more consecutive leads</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Uses of Rate-controlling Agent</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>includes use of Diltiazem, Esmolol, Metoprolol, Propranolol, Verapamil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Times an Anti-arrhythmic Agent is Used</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Corticosteroid</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>number of days participants received a corticosteroid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Direct Current (DC) Cardioversion Events</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Mechanical Ventilation Needed</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Hemodialysis Needed</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Sequential Organ Failure Assessment (SOFA) Score</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Predicts ICU mortality based on lab results and clinical data. Range is 0-24 with higher numbers indicating a higher risk of mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Peripheral Limb Ischemia</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiac Arrest Events</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Without Vasopressor Use</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Shock free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days Without Mechanical Ventilation</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Mechanical ventilation-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Without Dialysis</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Dialysis-free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Days Not in ICU</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>ICU free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days Spent Out of the Hospital</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Hospital free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission to ICU</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Rehospitalized After Discharge</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU Stay</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Mortality</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of Death</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of Death</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Troponin-I</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>From chart review (if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CK-MB</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>From chart review (if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Kinase (CK)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>From chart review (if available)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Receiving Non-study Vasopressors</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Time Non-study Vasopressors Used</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Blood Pressure (Maximum and Minimum)</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Central Venous Pressure</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Metabolic Panel Laboratory Values</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>From chart review (if available)</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Central Venous Oxygen Saturation</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>From chart review (if available)</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-hypertensive Agents Used</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diuretic Agents Used</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Inotropes Used</measure>
    <time_frame>Up to 28 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis</condition>
  <condition>Shock</condition>
  <condition>Tachycardia</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Phenylephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
    <arm_group_label>Phenylephrine</arm_group_label>
    <other_name>Neosynephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
    <arm_group_label>Norepinephrine</arm_group_label>
    <other_name>Levophed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years of age or greater

          -  Intention to treat with vasopressor for diagnosis of septic shock

          -  Exclusion criteria not met

        Exclusion Criteria:

          -  Emergent indication for surgery

          -  Patient possesses a terminal condition for which patient or medical decision maker has
             decided to de-escalate medical care (patients with Do Not Resuscitate order but for
             whom standard care is continued will not be excluded)

          -  Known allergy to phenylephrine or norepinephrine

          -  Treated with vasopressor &gt;12 hours for current episode of shock

          -  Preference of specific vasopressor agent by patient's provider

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj Keriwala, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>July 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2014</study_first_posted>
  <results_first_submitted>April 4, 2018</results_first_submitted>
  <results_first_submitted_qc>May 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 13, 2018</results_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Vasopressor Agents</keyword>
  <keyword>Phenylephrine</keyword>
  <keyword>Norepinephrine</keyword>
  <keyword>Tachycardia</keyword>
  <keyword>Heart Rate</keyword>
  <keyword>Arrhythmia</keyword>
  <keyword>Catecholamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phenylephrine</title>
          <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
        </group>
        <group group_id="P2">
          <title>Norepinephrine</title>
          <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phenylephrine</title>
          <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
        </group>
        <group group_id="B2">
          <title>Norepinephrine</title>
          <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="47" upper_limit="84"/>
                    <measurement group_id="B2" value="58.4" lower_limit="47" upper_limit="73"/>
                    <measurement group_id="B3" value="60.4" lower_limit="47" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Rate</title>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.3" lower_limit="60" upper_limit="119"/>
                    <measurement group_id="B2" value="97.3" lower_limit="60" upper_limit="132"/>
                    <measurement group_id="B3" value="92.4" lower_limit="60" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Blood Pressure</title>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.4" lower_limit="51" upper_limit="95"/>
                    <measurement group_id="B2" value="66.2" lower_limit="54" upper_limit="79"/>
                    <measurement group_id="B3" value="66.7" lower_limit="51" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Heart Rate</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Heart Rate</title>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="65" upper_limit="132"/>
                    <measurement group_id="O2" value="108.6" lower_limit="57" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Arrhythmia Events</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Arrhythmia Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Time in Arrhythmia</title>
        <time_frame>Up to 28 days</time_frame>
        <population>only participants with arrhythmias included</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Total Time in Arrhythmia</title>
          <population>only participants with arrhythmias included</population>
          <units>minutes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1224"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (undetermined) arrthymia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With ST-segment Abnormalities on ECG</title>
        <description>ST Elevation of 1 mm in 2 or more consecutive leads or Horizontal or downsloping ST depression of 1 mm in 2 or more consecutive leads</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With ST-segment Abnormalities on ECG</title>
          <description>ST Elevation of 1 mm in 2 or more consecutive leads or Horizontal or downsloping ST depression of 1 mm in 2 or more consecutive leads</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Uses of Rate-controlling Agent</title>
        <description>includes use of Diltiazem, Esmolol, Metoprolol, Propranolol, Verapamil</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Uses of Rate-controlling Agent</title>
          <description>includes use of Diltiazem, Esmolol, Metoprolol, Propranolol, Verapamil</description>
          <units>number of uses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Times an Anti-arrhythmic Agent is Used</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Times an Anti-arrhythmic Agent is Used</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Corticosteroid</title>
        <description>number of days participants received a corticosteroid</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Corticosteroid</title>
          <description>number of days participants received a corticosteroid</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Direct Current (DC) Cardioversion Events</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Direct Current (DC) Cardioversion Events</title>
          <units>DC cardioversion events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Mechanical Ventilation Needed</title>
        <time_frame>Up to 28 days</time_frame>
        <population>only participants that required mechanical ventilation</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Mechanical Ventilation Needed</title>
          <population>only participants that required mechanical ventilation</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Hemodialysis Needed</title>
        <time_frame>Up to 28 days</time_frame>
        <population>only participants that required dialysis</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Hemodialysis Needed</title>
          <population>only participants that required dialysis</population>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Sequential Organ Failure Assessment (SOFA) Score</title>
        <description>Predicts ICU mortality based on lab results and clinical data. Range is 0-24 with higher numbers indicating a higher risk of mortality</description>
        <time_frame>Up to 28 days</time_frame>
        <population>data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Sequential Organ Failure Assessment (SOFA) Score</title>
          <description>Predicts ICU mortality based on lab results and clinical data. Range is 0-24 with higher numbers indicating a higher risk of mortality</description>
          <population>data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Peripheral Limb Ischemia</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Peripheral Limb Ischemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiac Arrest Events</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiac Arrest Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Without Vasopressor Use</title>
        <description>Shock free days</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Without Vasopressor Use</title>
          <description>Shock free days</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days Without Mechanical Ventilation</title>
        <description>Mechanical ventilation-free days</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Without Mechanical Ventilation</title>
          <description>Mechanical ventilation-free days</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Without Dialysis</title>
        <description>Dialysis-free days</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Days Without Dialysis</title>
          <description>Dialysis-free days</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Days Not in ICU</title>
        <description>ICU free days</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Days Not in ICU</title>
          <description>ICU free days</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Spent Out of the Hospital</title>
        <description>Hospital free days</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Days Spent Out of the Hospital</title>
          <description>Hospital free days</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Readmission to ICU</title>
        <time_frame>Up to 28 days</time_frame>
        <population>data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Readmission to ICU</title>
          <population>data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Rehospitalized After Discharge</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Rehospitalized After Discharge</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of ICU Stay</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Length of ICU Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O2" value="5.2" lower_limit="2" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O2" value="8.9" lower_limit="3" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>28-day Mortality</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>28-day Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Location of Death</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Location of Death</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not recorded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause of Death</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Cause of Death</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E. coli bacteremia, aspiration pnemonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory failure,hospital aquired pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>septic shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoxemic respiratory failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Troponin-I</title>
        <description>From chart review (if available)</description>
        <time_frame>Up to 28 days</time_frame>
        <population>patients with troponin levels</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Troponin-I</title>
          <description>From chart review (if available)</description>
          <population>patients with troponin levels</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" lower_limit="0.22" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.1" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CK-MB</title>
        <description>From chart review (if available)</description>
        <time_frame>Up to 28 days</time_frame>
        <population>patients with CK-MB levels</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>CK-MB</title>
          <description>From chart review (if available)</description>
          <population>patients with CK-MB levels</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.87" lower_limit="8.87" upper_limit="8.87"/>
                    <measurement group_id="O2" value="5.07" lower_limit="5.07" upper_limit="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Kinase (CK)</title>
        <description>From chart review (if available)</description>
        <time_frame>Up to 28 days</time_frame>
        <population>patients with CK levels</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Kinase (CK)</title>
          <description>From chart review (if available)</description>
          <population>patients with CK levels</population>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738" lower_limit="738" upper_limit="738"/>
                    <measurement group_id="O2" value="6986.6" lower_limit="242" upper_limit="13211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Receiving Non-study Vasopressors</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Non-study Vasopressors</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Time Non-study Vasopressors Used</title>
        <time_frame>Up to 28 days</time_frame>
        <population>participants receiving non-study vasopressors</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Time Non-study Vasopressors Used</title>
          <population>participants receiving non-study vasopressors</population>
          <units>hours</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phenylephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norepinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasopressin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Blood Pressure (Maximum and Minimum)</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Pressure (Maximum and Minimum)</title>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>minimum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="40" upper_limit="63"/>
                    <measurement group_id="O2" value="53.8" lower_limit="42" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maximum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.6" lower_limit="77" upper_limit="109"/>
                    <measurement group_id="O2" value="79.5" lower_limit="71" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Central Venous Pressure</title>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Central Venous Pressure</title>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Metabolic Panel Laboratory Values</title>
        <description>From chart review (if available)</description>
        <time_frame>Up to 28 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Central Venous Oxygen Saturation</title>
        <description>From chart review (if available)</description>
        <time_frame>Up to 28 days</time_frame>
        <population>patients with central venous pressure readings</population>
        <group_list>
          <group group_id="O1">
            <title>Phenylephrine</title>
            <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
          <group group_id="O2">
            <title>Norepinephrine</title>
            <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Central Venous Oxygen Saturation</title>
          <description>From chart review (if available)</description>
          <population>patients with central venous pressure readings</population>
          <units>mm/Hg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="O2" value="11.7" lower_limit="7" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Anti-hypertensive Agents Used</title>
        <time_frame>Up to 28 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Diuretic Agents Used</title>
        <time_frame>Up to 28 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Inotropes Used</title>
        <time_frame>Up to 28 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events and Serious adverse events will not include organ failure or death that is related to septic shock, which are expected complications in this population, unless they are more severe than is expected or unusual in their happenstances.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phenylephrine</title>
          <description>Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
Phenylephrine: Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
        </group>
        <group group_id="E2">
          <title>Norepinephrine</title>
          <description>Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
Norepinephrine: Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to slow enrollment, lack of support and equipoise. PI left Vanderbilt and the record was completed with data recorded in REDCap.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raj Keriwala</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-322-3412</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

